This content is machine translated Polymyalgia rheumatica and giant cell arteritis New consensus paper recommends “treat-to-target” strategy Giant cell arteritis and polymyalgia rheumatica are inflammatory rheumatic diseases that often occur together and almost exclusively affect people over the age of 50. Glucocorticoids are initially used for both…
View Post 6 min This content is machine translated Giant cell arteritis: classification and treatment What’s new? Das vom American College of Rheumatology (ACR) und der European League against Rheumatology (EULAR) gemeinsam entwickelte und 2022 veröffentlichte Update der Klassifikationskriterien für Riesenzellarteriitis trägt insbesondere den Fortschritten im Bereich…
View Post 17 min This content is machine translated Systemic vasculitides Therapy in the adult patient Systemic vasculitides are inflammatory syndromes of the blood vessels, which can cause a very broad spectrum of symptoms depending on the affected vessel caliber and localization. The most common primary…
View Post 2 min This content is machine translated Giant cell arteritis Indication expansion of Actemra® in Switzerland Until now, only high-dose steroids have been available for the potentially life-threatening autoimmune disease giant gall arteritis. This has changed with the first commercially available non-steroidal biotherapeutic targeting the IL-6…
View Post 7 min This content is machine translated Peripheral arterial occlusive disease Rare causes and differential diagnoses The clinic of degenerative changes is difficult to distinguish from that of peripheral arterial disease (PAVD), and measurement of ABI is indicative.
View Post 4 min This content is machine translated Three-country conference on headache in Bad Zurzach Giant cell arteritis – Dangerous inflammation of the blood vessels The course of giant cell arteritis is chronic. Patients often suffer from headache. In order to therapeutically save steroids, the monoclonal antibody tocilizumab has recently been used.
